Radcliffe Capital Management’s LAVA Medtech Acquisition Corp. Class A Common Stock LVAC Stock Holding History

Radcliffe Capital Management’s Portfolio LVAC Stock Details LVAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-199,350	Closed	-$2.08M	–	659
2023 Q1	$2.08M	Buy	199,350 +69,762	+54%	+$722K	0.13%	223
2022 Q4	$1.33M	Hold	129,588	–	–	0.04%	586
2022 Q3	$1.3M	Buy	129,588 +99	+0.1%	+$992	0.03%	817
2022 Q2	$1.29M	Buy	129,489 +2,220	+2%	+$22.2K	0.03%	861
2022 Q1	$1.27M	Buy	127,269 +27,269	+27%	+$271K	0.03%	849
2021 Q4	$1M	Buy	+100,000	New	+$990K	0.03%	811

Radcliffe Capital Management's LVAC Position: Q2 2023 in Review

Radcliffe Capital Management sold out of LAVA Medtech Acquisition Corp. Class A Common Stock (LVAC) in Q2 2023, closing a stake of 199,350 shares — an estimated $2.08M sold.

Radcliffe Capital Management first reported a position in LVAC in Q4 2021 and held it in 6 quarters. The position peaked at $2.08M in Q1 2023. 0 funds tracked by Wall St. Rank hold LVAC as of Q2 2023.

Radcliffe Capital Management reported no remaining LAVA Medtech Acquisition Corp. Class A Common Stock position as of Q2 2023 after selling out during the quarter.
Radcliffe Capital Management sold 199,350 LAVA Medtech Acquisition Corp. Class A Common Stock shares in Q2 2023, an estimated $2.08M.
Radcliffe Capital Management first reported a position in LAVA Medtech Acquisition Corp. Class A Common Stock in Q4 2021 and held it in 6 quarters.
Radcliffe Capital Management's LAVA Medtech Acquisition Corp. Class A Common Stock position peaked at $2.08M in Q1 2023.
0 funds tracked by Wall St. Rank held LAVA Medtech Acquisition Corp. Class A Common Stock as of Q2 2023.

Based on Radcliffe Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.